PDB 093Alternative Names: WAY PDB 093
Latest Information Update: 23 Jan 2001
At a glance
- Originator Wyeth
- Class Antiasthmatics; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 23 Jan 2001 Discontinued-Preclinical for Asthma in USA (Unknown route)
- 23 Jul 1998 No-Development-Reported for Asthma in USA (Unknown route)
- 09 May 1995 New profile